Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...
The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...
During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...
Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment ...
Merck and its rivals make tens of billions of dollars a year from the mechanism and are ... regardless of PD-L1 expression. Junshi, Coherus' PD-1 inhibitor Loqtorzi scores in phase 3 liver cancer ...
BeiGene’s trials suggest that this mechanism, combined with chemotherapy, offers survival benefits in PD-L1-expressing cancers. Tevimbra is part of a competitive PD-1 inhibitor market ...
NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...
The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback